

CONFIDENTIAL



NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(b)

Subject: Notification Pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont:

Genentech USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug, pursuant to 18 V.S.A. § 4637(b):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Lunsumio 1mg/1mL	50242-0159-01	January 9, 2023	\$ 594.06
Lunsumio 30mg/30mL	50242-0142-01	January 9, 2023	\$17,821.78

Frances Baffoe-Harding
State Government Programs Manager
Genentech USA, Inc.